Engineers Gate Manager LP Neurocrine Biosciences Inc Transaction History

Engineers Gate Manager LP

$7.46 Billion
Q2 2025

A detailed history of Engineers Gate Manager LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Engineers Gate Manager LP holds 5,392 shares of NBIX stock, worth $769,168. This represents 0.01% of its overall portfolio holdings.

Number of Shares

5,392

Previous 3,119 72.88%

Holding current value

$769,168

Previous $344,000 96.8%

% of portfolio

0.01%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$87.54 - $128.18 $198,978 - $291,353	2,273 Added 72.88%	5,392 $677,000
Q1 2025 May 15, 2025	SELL	$107.22 - $153.29 $1.7 Million - $2.43 Million	-15,847 Reduced 83.55%	3,119 $344,000
Q4 2024 Feb 14, 2025	SELL	$111.62 - $139.44 $6.44 Million - $8.04 Million	-57,656 Reduced 75.25%	18,966 $2.59 Million
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $4.81 Million - $6.43 Million	41,978 Added 121.17%	76,622 $8.82 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $2.3 Million - $2.51 Million	17,542 Added 102.57%	34,644 $4.77 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $976,304 - $1.08 Million	7,487 Added 77.87%	17,102 $2.36 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $1.4 Million - $1.75 Million	-13,205 Reduced 57.87%	9,615 $1.27 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $548,324 - $682,927	5,832 Added 34.33%	22,820 $2.57 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $65,715 - $76,974	-734 Reduced 4.14%	16,988 $1.6 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $1.28 Million - $1.68 Million	13,625 Added 332.56%	17,722 $1.79 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $437,231 - $520,564	4,097 New	4,097 $489,000
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $116,640 - $154,007	1,539 Added 41.34%	5,262 $513,000
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $70,711 - $92,534	976 Added 35.53%	3,723 $349,000
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $311,351 - $415,213	-3,909 Reduced 58.73%	2,747 $234,000
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $443,740 - $509,905	-5,149 Reduced 43.62%	6,656 $638,000
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $1.06 Million - $1.21 Million	11,805 New	11,805 $1.15 Million
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $1.1 Million - $1.37 Million	-12,618 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $863,805 - $1.21 Million	8,983 Added 247.13%	12,618 $1.21 Million
Q2 2020 Aug 17, 2020	BUY	$85.09 - $130.36 $79,048 - $121,104	929 Added 34.33%	3,635 $443,000
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $1.61 Million - $2.43 Million	-21,399 Reduced 88.77%	2,706 $234,000
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $1.62 Million - $2.21 Million	18,635 Added 340.68%	24,105 $2.59 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $458,495 - $555,205	5,470 New	5,470 $493,000
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $173,376 - $219,048	-2,400 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $166,344 - $219,672	2,400 New	2,400 $211,000

Others Institutions Holding NBIX

# of Institutions

663

Shares Held

102M

Call Options Held

290K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.6B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.

Account

Engineers Gate Manager LP Neurocrine Biosciences Inc Transaction History